Neurodyn Life Sciences Inc. announced completion of its first-in-human clinical study, demonstrating Memogain’s potential benefits over existing Alzheimer’s drugs: increased safety in the absence of significant side effects and more potent cognitive enhancement.
Positive Phase 1A Outcome for Memogain® Means Potential New Treatment for Alzheimer’s Disease
This entry was posted in Mertzholdings News. Bookmark the permalink.